KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardlytics (CDLX) EBT Margin (2017 - 2025)

Historic EBT Margin for Cardlytics (CDLX) over the last 9 years, with Q3 2025 value amounting to 139.67%.

  • Cardlytics' EBT Margin rose 768300.0% to 139.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 44.12%, marking a year-over-year increase of 494300.0%. This contributed to the annual value of 68.02% for FY2024, which is 244600.0% down from last year.
  • Per Cardlytics' latest filing, its EBT Margin stood at 139.67% for Q3 2025, which was up 768300.0% from 14.68% recorded in Q2 2025.
  • Cardlytics' 5-year EBT Margin high stood at 48.64% for Q1 2022, and its period low was 458.5% during Q4 2022.
  • Over the past 5 years, Cardlytics' median EBT Margin value was 30.65% (recorded in 2023), while the average stood at 73.5%.
  • In the last 5 years, Cardlytics' EBT Margin plummeted by -4366300bps in 2022 and then soared by 3454200bps in 2023.
  • Quarter analysis of 5 years shows Cardlytics' EBT Margin stood at 21.88% in 2021, then crashed by -1996bps to 458.5% in 2022, then surged by 75bps to 113.09% in 2023, then surged by 81bps to 21.07% in 2024, then plummeted by -563bps to 139.67% in 2025.
  • Its EBT Margin stands at 139.67% for Q3 2025, versus 14.68% for Q2 2025 and 21.46% for Q1 2025.